@article{f89f6891ed324c24bac09d6fb2010320,
title = "Effective omalizumab interval prolongation in the treatment of chronic urticaria",
author = "\{Alizadeh Aghdam\}, Mehran and Pieterse, \{Rianne Henri{\"e}tte\} and Kentie, \{Petra Adriana\} and Feiko Rijken and Knulst, \{Andr{\'e} Cornelis\} and Heike R{\"o}ckmann",
note = "Funding Information: No funding was received for this work. Conflicts of interest: A. C. Knulst is a member of advisory board of Novartis; and has health care innovation grant from Novartis to institution. H. R{\"o}ckmann is a member of national advisory board of Novartis. The rest of the authors declare that they have no relevant conflicts of interest.",
year = "2020",
month = nov,
day = "1",
doi = "10.1016/j.jaip.2020.06.056",
language = "English",
volume = "8",
pages = "3667--3668.e1",
journal = "Journal of Allergy and Clinical Immunology: In Practice",
issn = "2213-2198",
publisher = "American Academy of Allergy, Asthma and Immunology",
number = "10",
}